Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
about
Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providersOnce-weekly albiglutide in the management of type 2 diabetes: patient considerations.Osteoporosis therapies: evidence from health-care databases and observational population studies.Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational StudyAssessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture.Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional studyOsteoporosis medication profile preference: results from the PREFER-US studyAdherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review.Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study.Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases.Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis.Antiresorptive therapies for osteoporosis: a clinical overview.Adherence with medications used to treat osteoporosis: behavioral insights.A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study.Understanding patient compliance and persistence with osteoporosis therapy.Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
P2860
Q28744535-CFA6DC82-D508-41ED-8CE2-7C76DBF3861FQ33728226-03AD89A3-CFB1-4D2E-9ACB-94C5A016E092Q34242906-B20D80FD-4493-473B-AC49-BEF46B3B5333Q34529920-EC3BDAFE-D21C-44B3-A0DA-26A57DCA0F19Q35017714-898B9090-0A3C-45BD-8081-7265D49AD82CQ35050249-7C2E57E6-1541-4D65-8F24-E43B0E010267Q35371081-97E3408B-358E-40D1-8CA8-32497F3063D5Q36056911-77BE715C-20A5-4C7C-98EA-E9D3512A8FD0Q36073613-00F5645A-7EE2-499E-B228-278FF99E583CQ36088579-961BD079-D7E7-4733-A3A9-97802F4CE6CFQ37360702-0274C29C-3BFB-465C-B7EB-5BBC259250BEQ37422363-8ACCA54D-6986-4F2A-9FEC-1521DB9F7F48Q37684745-C0292EB9-C89C-4D62-BC4B-2C6FDF48E05EQ37813135-2420E80C-1A12-4E30-82CA-8E7D6AB7C531Q37926914-922D705F-AB3D-46D2-A8A4-7A54187C8573Q38075457-2E808C90-4E62-4E82-A323-293409EDCDB2Q38241347-0600BE2E-55F7-44B1-9B29-3EE3B8824D21Q44745930-A2A9C95B-21FB-4B99-83FD-D650A38237F4Q50568548-9BFA09A8-CFF1-46B4-8EEC-E9228173C04BQ50629816-B7F94F71-B3CC-4BA9-8A90-34B8FDA5DDC6Q51008584-F624A403-C000-4151-92D1-41DDC8F56793
P2860
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Adherence and persistence asso ...... sis in a managed care setting.
@en
Adherence and persistence asso ...... sis in a managed care setting.
@nl
type
label
Adherence and persistence asso ...... sis in a managed care setting.
@en
Adherence and persistence asso ...... sis in a managed care setting.
@nl
prefLabel
Adherence and persistence asso ...... sis in a managed care setting.
@en
Adherence and persistence asso ...... sis in a managed care setting.
@nl
P2093
P1476
Adherence and persistence asso ...... sis in a managed care setting.
@en
P2093
Kristijan H Kahler
Mohamed A Omar
Stephen J Boccuzzi
Susan H Foltz
Timothy W Downey
P304
P356
10.1097/01.SMJ.0000221637.90495.66
P407
P577
2006-06-01T00:00:00Z